Traditional Chinese medicine, Danlou tablets alleviate adverse left ventricular remodeling after myocardial infarction: results of a double-blind, randomized, placebo-controlled, pilot study

Table 2 Echocardiogaphic LV remodeling end points

	Danlou tablets (n = 42)			Placebo (n = 41)			Danlou tablets vs. Placebo	P
	Baseline	90 days	Change	Baseline	90 days	Change	Difference in change (95 % CI)	P
LVEDVi, mL/m²	49.22 ± 8.70	44.73 ± 4.29	−4.49 ± 7.29	51.33 ± 9.61	50.99 ± 3.55	−0.34 ± 9.01	−5.86 (−7.55 to −4.16)	<0.001
LEVSVi, mL/m²	31.79 ± 5.29	27.69 ± 2.46	−4.09 ± 5.85	31.05 ± 6.02	30.51 ± 3.12	−0.54 ± 5.72	−3.20 (−4.43 to −1.98)	<0.001
LVEF,%	44.76 ± 7.95	49.59 ± 3.29	4.83 ± 9.23	46.79 ± 8.03	46.53 ± 2.97	0.23 ± 8.15	3.15 (1.66 to 4.63)	<0.001

Values are expressed as means ± SD when appropriate
CI confidence interval, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume index, LVEF left ventricular ejection fraction

ISSN: 2662-7671